GSK Plc (GSK)
48.07
+0.42
(+0.88%)
USD |
NYSE |
Jan 21, 16:00
47.92
-0.15
(-0.31%)
Pre-Market: 07:52
GSK Cash from Investing (Quarterly): -2.150B for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| AstraZeneca PLC | -2.088B |
| Biodexa Pharmaceuticals Plc | -- |
| AnaptysBio, Inc. | 103.28M |
| NuCana Plc | -0.0656M |
| Mereo BioPharma Group Plc | 0.3027M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 3.028B |
| Cash from Financing (Quarterly) | -1.707B |
| Free Cash Flow | 5.645B |
| Free Cash Flow Per Share (Quarterly) | 0.8897 |
| Free Cash Flow to Equity (Quarterly) | 1.710B |
| Free Cash Flow to Firm (Quarterly) | 2.021B |
| Free Cash Flow Yield | 5.70% |